SciELO - Scientific Electronic Library Online

 
vol.42 número5Reacciones adversas asociadas a la vacuna del meningococo B (4CMenB) en adultos en situaciones especialesEvaluación de la experiencia del paciente VIH+ con la atención farmacéutica basada en la metodología CMO índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Farmacia Hospitalaria

versión On-line ISSN 2171-8695versión impresa ISSN 1130-6343

Farm Hosp. vol.42 no.5 Toledo sep./oct. 2018

http://dx.doi.org/10.7399/fh.10899 

BRIEF ORIGINALS

Prevalence of medication-related problems in complex chronic patients and opportunities for improvement

Marta Guerro-Prado1  , María Adelina Olmo-Revuelto1  , Miguel Ángel Catalá-Pindado1 

1Servicio de Farmacia, Hospital Universitario Río Hortega, Valladolid. Spain.

Abstract

Objective:

To estimate the prevalence of medication-related problems in patients treated in continuous care units and to identify the therapeutic areas in which these problems were more concentrated.

Method:

Observational descriptive prospective study. Review of clinical histories and outpatient treatment by a hospital pharmacist. Communicating medication-related problems detected to the responsible doctor. Analysis of the therapeutic areas in which the problems were most concentrated.

Results:

85 patients were reviewed, and 368 potential medication-related problems were identified. The areas with the most prevalent medication-related problems were the long-term use of hypnotics, sub-optimal analgesia, optimizable antidepressant treatment, statins in patients older than 75 years in primary prevention and in those with high-intensity doses in secondary prevention, patients with heart failure without angiotensin-converting enzyme inhibitors, and proton-pump inhibitors without indication.

Conclusions:

Training interventions should be implemented and computer assistance should be developed to help avoid the most prevalent medication-related problems.

KEYWORDS: Primary Health Care; Continuity of patient care; Chronic disease; Comorbidity; Intermediate care; Medication-related problems

Resumen

Objetivo:

Estimar la prevalencia de problemas relacionados con la medicación en los pacientes atendidos en la consulta de la unidad de continuidad asistencial e identificar las áreas terapéuticas donde se concentran.

Método:

Estudio observacional descriptivo y prospectivo. Revisión de la historia clínica y el tratamiento domiciliario por un farmacéutico hospitalario y comunicación al médico de los problemas relacionados con la medicación detectados. Análisis de las áreas terapéuticas donde se concentran.

Resultados:

Se revisaron 85 pacientes, identificando 368 potenciales problemas relacionados con la medicación. Las áreas más prevalentes fueron el uso crónico de hipnóticos, la analgesia subóptima, el tratamiento antidepresivo optimizable, estatinas en mayores de 75 años en prevención primaria y con dosis altas en prevención secundaria, pacientes con insuficiencia cardiaca sin inhibidores de la enzima convertidora de angiotensina e inhibidores de la bomba de protones sin indicación.

Conclusiones:

Se deberían realizar intervenciones formativas y desarrollar asistencias informáticas que ayuden a evitar los problemas más prevalentes relacionados con la medicación.

PALABRAS CLAVE: Atencion Primaria de Salud; Continuidad de la atención al paciente; Enfermedad crónica; Pluripatológico; Atención intermedia; Problemas relacionados con la medicación

Introduction

Chronic diseases are the main cause of mortality and disability in developed countries. To adapt the healthcare model to this situation, the Autonomous Community of Castile and León (Spain) has designed a strategy for the care of chronic patients1 by creating Continuous Care Units (CCU) in hospitals, with a specialist in Internal Medicine acting as an intermediary and consultant for Primary Care physicians (PCP).

One of the main challenges in the management of chronic patients is related to pharmacotherapy: There is a lack of evidence due to the exclusion of these types of patients from clinical trials, clinical practice guidelines address the management of a single disease2, and this group of patients is particularly frail. In recent years, different methods have emerged to adapt treatments to these patients3,4, but their implementation in daily clinical practice is difficult. Depending on the care setting under study and the tool used for assessment, the prevalence of medication-related problems (MRPs) ranges from 22% to 33% in Spain5,6.

This study estimated the prevalence of MRPs in complex chronic patients (CCP) treated in the CCU, and identified the therapeutic areas with the highest concentration of MRPs and the greatest margin for improvement.

Methods

Observational descriptive prospective study of the prevalence of MRPs in CCP treated in the CCU from June to December 2016. To fulfil one of the objectives of the yearly management plan of the Autonomous Community, the work methodology was consensually designed at a joint meeting of the medical management of the hospital, the internists from the CCU, and the pharmacy service. The study included all the outpatients with electronic prescriptions to ensure that a complete and updated list of the home treatment of each study participant was available. A hospital pharmacist reviewed the electronic medical record of each patient, both from primary care (Medora®) and specialized care (SiClínica®), and systematically checked the following treatment-related items:

Current indication, validated and registered in the medical record.

Evidence related to the drug (reviewed in UpToDate, Cochrane, Trip Database, and using the Beers3 and Stopp-Start4 criteria).

Absence of duplication.

Absence of interactions with other drugs or with preexisting pathologies.

Appropriate dosage: optimal schedule and adjustment to renal function, weight, and age.

Patient follow-up and periodic monitoring needed.

Selection of the safest, most effective, and cheapest drug.

Absence of unaddressed indications.

Based on the type of negative results associated with medication (NRMs), the MRPs detected were classified into: need, safety, and effectiveness7.

A list of the MRPs detected and their proposed solutions were sent by e-mail to the physician responsible for the CCU the day before the appointment with the patient. The physician assessed the solutions proposed for these MRPS and decided if they were applicable or not. If the solutions were accepted, they were registered in the patients’ electronic medical record. If the physician rejected the solution or considered that it should be assessed by the PCP, the pharmacist was contacted by telephone.

Results

In total, 85 complex patients with electronic prescriptions were treated in the CCU during the study period. Mean age was 83.7 years (range = 61-98) and 53.7% of the participants were women. A total of 1125 treatment lines were reviewed ( = 13.2 lines/patient, standard deviation = 3.97). We identified 368 potential MRPs (median = 4 MRPs/patient; interquartile range = 3-6), entailing a prevalence of 32.7 MRPs/100 treatment lines.

Table 1 shows the MRPs detected, which were classified as follows: need NRMs = 125/368 (34%); safety NRMs = 92/368 (25%); and effectiveness NRMs = 151/368 (41%).

Table 1 Detected medication-related problem and negative results associated with medication 

MRP: medication-related problem; NRM: negative results associated with medication.

Regarding the pharmacist’s recommendations, 35.3% were accepted by the physician responsible for the CCU, while the remaining 64.7% were deemed to require assessment by the PCP. None of the solutions were rejected. In total, 105 of the proposed solutions were not assessed for the following reasons: 45 e-mails were not read because of lack of time; 25 solutions were not assessed due to software problems; 24 were not assessed because the patient did not attend the appointment; and 11 were not assessed because the patient died.

The most prevalent problems were found in the following therapeutic areas:

Long-term use of hypnotics (23.5%).

Sub-optimal analgesia (23.5%).

Optimizable antidepressant treatment (14.1%).

Use of statins in patients over 75 years in primary prevention (9.4%) and with high-intensity doses in secondary prevention (4.7%).

Patients diagnosed with heart failure not treated with angiotensin-converting enzyme inhibitors (ACEIs) (10.6%).

Use of proton-pump inhibitors (PPIs) without valid indication (8.2%).

Discussion

The prevalence of MRPs (32.7%) in this study was similar to that described in previous studies5,6; however, the patients are not fully comparable because both the average age of the participants and the number of drugs prescribed were higher in our study. We found that the long-term use of hypnotics and inappropriate use of PPIs were two of the therapeutic areas associated with more MRPs, which is line with the findings of previous studies5,6. However, we also identified other therapeutic areas with large numbers of MRPs; thus, further research is warranted.

To better understand the magnitude of these results, we extrapolated them to the 62,700 CCP in the Autonomous Community of Castile and León (see Table 2). Thus, 14,734 patients would have prescriptions for the long-term use of hypnotics for chronic insomnia, with the consequent risk of falls, confusion, and excessive daytime sleepiness8; 14,734 patients would have the opportunity for improved analgesic treatment; 8,841 would have an inappropriate prescription for antidepressant drugs (e.g. caused by not taking into account their potential for interactions with comorbidities or concomitant drugs); 5,894 patients over 75 years would be treated with statins in primary prevention and 2,945 patients over 75 years would be treated with high-intensity doses in secondary prevention: statins have not been shown to have any benefits in these situations, but have been shown to increase the risk of myopathy, diabetes, and cognitive abnormalities9; 6,646 patients with congestive heart failure and LVEF < 40% would not have been treated with ACEIs, although they have been shown to reduce morbidity and mortality10; and 5,141 patients would have been treated with PPIs without indications, which would have increased the risk of pneumonia, overinfection by Clostridium difficile, and vitamin B12, iron, and calcium deficiencies11.

Table 2 Most prevalent medication-related problems extrapolated to all CCP patients in the Autonomous Community of Castile and León (Spain) 

ACEI: angiotensin-converting enzyme inhibitor.

One of the limitations of this study is that only 45% of the patients treated in the CCU had an electronic prescription, which may have biased the results. Moreover, the CCU physician considered that most of the recommendations (64.7%) required assessment by the PCP; however, the number of recommendations that were accepted remains unknown. Given our results and those described in previous studies12, we recommend the creation of multidisciplinary teams comprising all the professionals involved in the different levels of care in the treatment of CCP, and also recommend the development of training interventions and computer assistance to help avoid the most prevalent MRPs.

Contribution to scientific literature

This study tries to identify the main problems related to medication (MPRs) in CCP. Although in recent years different methods have emerged for the adequacy of treatment in this type of patients, its application in daily clinical practice is very complicated. Identifying the main problems related to medication (PRMs) in these patients, training interventions and computer assistance could be developed, facilitating the management of pharmacotherapy in CCP.

Bibliography

Estrategia de atención al paciente crónico en Castilla y León (consultado 03/2017). Disponible en: www.saludcastillayleon.es/institucion/es/planes-estrategias. [ Links ]

Dumbreck S, Flynn A, Nairn M, Wilson M, Treweek S, Mercer SW, et al. Drugdisease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ. 2015;350:949. DOI: 10.1136/bmj.h949 [ Links ]

Fick DM, Semla TP, Beizer J, Brandt N, Dombrowski R, DuBeau CE, et al. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11):2227-46. DOI: 10.1111/jgs.13702 [ Links ]

Delgado Silveira E, Montero Errasquín B, Muñoz García M, Vélez-Díaz-Pallarés M, Lozano Montoya I, Sánchez-Castellano C, et al. Mejorando la prescripción de medicamentos en las personas mayores: una nueva edición de los criterios STOPP-START. Rev Esp Geriatr Gerontol. 2015;50(2):89-96. DOI: 10.1016/j.regg.2014.10.005 [ Links ]

Parodi López N, Villán Villán YF, Granados Menéndez MI, Royuela A. Potentially inappropriate prescribing in patients over 65 years-old in a primary care health centre. Aten Primaria. 2014;46(6):290-7. DOI: 10.1016/j.aprim.2013.12.007 [ Links ]

Mud F, Mud S, Rodríguez MJ, Ivorra MD, Ferrándiz ML. Detección de prescripciones potencialmente inapropiadas en pacientes ancianos: estudio descriptivo en dos farmacias comunitarias. Farmacéuticos Comunitarios. 2014;6(2):20-6. DOI:10.5672/FC.2173-9218.(2014/Vol6).002.04 [ Links ]

Grupo de Investigación en Atención Farmacéutica. Universidad de Granada. Grupo de Investigación en Farmacología. Universidad de Granada. Fundación Pharmaceutical Care España. Sociedad Española de Farmacia Comunitaria. Tercer Consenso de Granada sobre Problemas Relacionados con Medicamentos (PRM) y Resultados Negativos asociados a la Medicación (RNM). Ars Pharm. 2007; 48:5-17. [ Links ]

Longo LP et al. Addiction: Part I. Benzodiazepines side effects, abuse risk and alternatives. Am Fam Physician. 2000;61(7):2121-8. [ Links ]

Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. J Am Coll Cardiol. 2014;63(25 Pt B):2889-934. DOI: 10.1016/j.jacc.2013.11.002 [ Links ]

National Institute for Clinical Excellence, NICE. Chronic heart failure in adults: management. NICE guidance (CG108) Agosto 2010 (consultado 06/2016). Disponible en: www.nice.org.uk/guidance/cg108Links ]

Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122:896-903. DOI: 10.1016/j.amjmed.2009.04.014. Review. [ Links ]

Romero-Ventosa EY, Samartín-Ucha M, Martín-Vila A, Martínez-Sánchez ML, Rey Gómez-Serranillos I, Pineiro-Corrales G. Equipos multidisciplinares comprometidos: detección de problemas relacionados con los medicamentos a través de la continuidad asistencial. Farm Hosp 2016; 40 (6):529-43. DOI: 10.7399/fh.2016.40.6.10506 [ Links ]

Received: September 20, 2017; Accepted: April 20, 2018

Autor para correspondencia. 28. Correo electrónico: maguerropr@saludcastillayleon.es (Marta Guerro Prado).

Conflict of interests

31. No conflict of interests.

Creative Commons License This is an open-access article distributed under the terms of the Creative Commons Attribution License